Table 1.

Multivariate analysis of factors associated with survival and progression of patients with glioblastoma

SurvivalMedian survival (months, 95% CI)HR (95% CI)P
OS
 LGALS3 (High vs. low)10 (8.454–11.546) vs. 18 (13.335–22.665)1.946 (1.304–2.904)0.001
 Chemotherapy (yes vs. no)14 (15.303–24.688) vs. 9 (7.513–15.901)0.626 (0.406–0.967)0.035
PFS
 LGALS3 (High vs. low)7 (5.444–8.556) vs. 15 (9.010–20.99)2.294 (1.504–3.499)0.001
 Radiotherapy (yes vs. no)11 (8.993–13.007) vs. 8 (6.156–9.844)0.600 (0.381–0.945)0.027
 Gender (female vs. male)11 (6.664–15.336) vs. 9 (6.115–11.885)0.514 (0.325–0.812)0.004